Logo

NTRB

Nutriband Inc.

NTRB

Nutriband Inc. • NASDAQ
$4.92 ▲ 1.44% (+0.07)
Market Cap $54.91 M
52w High $11.78
52w Low $3.72
Dividend Yield 0%
P/E -1.7
Volume 10.45K
Outstanding Shares 11.16M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $622.452K ▼ $2.16M ▲ $-2M ▼ -321.364% ▼ $-2.12 ▼ $-1.946M ▼
Q1-2025 $667.432K ▲ $1.657M ▼ $-1.389M ▲ -208.111% ▲ $-0.12 ▲ $-1.326M ▲
Q4-2024 $642.379K ▼ $2.238M ▲ $-5.516M ▼ -858.683% ▼ $-0.51 ▼ $-5.44M ▼
Q3-2024 $645.796K ▲ $1.606M ▲ $-1.363M ▲ -211.057% ▲ $-0.12 ▲ $-1.285M ▲
Q2-2024 $442.83K $1.501M $-1.705M -385.024% $-0.15 $-1.63M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $6.995M ▲ $10.177M ▲ $1.683M ▲ $8.494M ▲
Q1-2025 $2.964M ▼ $6.152M ▼ $1.049M ▲ $5.103M ▼
Q4-2024 $4.312M ▼ $7.47M ▼ $1.041M ▼ $6.429M ▼
Q3-2024 $5.698M ▼ $12.543M ▼ $1.312M ▲ $11.232M ▼
Q2-2024 $6.76M $13.634M $1.173M $12.461M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-2M ▼ $-1.313M ▲ $5.324K ▲ $5.344M ▲ $4.031M ▲ $-1.308M ▲
Q1-2025 $-1.389M ▲ $-1.337M ▼ $-5.324K ▼ $-5.326K ▲ $-1.348M ▲ $-1.337M ▼
Q4-2024 $-5.516M ▼ $-1.239M ▼ $0 ▲ $-147.224K ▼ $-1.386M ▼ $-1.239M ▼
Q3-2024 $-1.363M ▲ $-1.01M ▲ $-46.958K ▼ $-5.175K ▼ $-1.062M ▲ $-1.057M ▲
Q2-2024 $-1.705M $-1.544M $-38.89K $-5.136K $-1.588M $-1.583M

Five-Year Company Overview

Income Statement

Income Statement Nutriband looks like a classic early-stage biotech: it has essentially no recorded product revenue yet and continues to report losses each year. Earnings per share have been consistently negative, which reflects ongoing spending on research, development, and overhead without commercial sales to offset those costs. The pattern is choppy rather than steadily improving, suggesting the business is still in its build-out and development phase rather than approaching profitability. Future income statement health will depend heavily on whether its lead products clear regulatory hurdles and start generating meaningful, recurring revenue.

Balance Sheet

Balance Sheet The balance sheet appears very small and simple, with modest total assets, no reported debt, and equity funding as the main financial backbone. This means the company is not weighed down by borrowings, which reduces financial leverage risk, but also indicates a limited resource base to fund a long and expensive development path on its own. The thin equity cushion suggests the business likely depends on external capital raises and partnership arrangements to advance its pipeline and cover operating costs. Overall, financial resilience looks modest and closely tied to the company’s ability to keep attracting funding.

Cash Flow

Cash Flow Reported cash flow figures are essentially flat, which likely reflects limited historical scale and some rounding, rather than a truly neutral cash position. Conceptually, as a pre-revenue biotech focused on R&D, Nutriband is almost certainly using cash for development work, regulatory preparation, and corporate operations, while replenishing that cash through equity issues and warrant exercises, as noted recently. The key cash flow question is not past performance but whether future funding and potential partnership or milestone payments are sufficient to support development through clinical, regulatory, and launch stages without creating financial strain.

Competitive Edge

Competitive Edge Competitively, Nutriband is trying to carve out a distinct niche rather than compete head-on with large drug makers across many areas. Its focus on abuse-deterrent transdermal patches, especially for opioids, gives it a targeted value proposition in a space where safety and misuse prevention are major public and regulatory concerns. A wide patent estate across many regions and a development and manufacturing partnership with an established transdermal specialist strengthen its position. On the other hand, the company is small and early-stage, with no commercial flagship product yet, so its competitive strength remains largely potential and depends on successful execution, regulatory approvals, and eventual market uptake against larger, well-funded players and existing therapies.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Nutriband’s story. The AVERSA platform is designed to make transdermal patches harder to abuse by layering in aversive components that do not touch the skin but strongly discourage tampering or oral misuse. Structuring products to use an FDA pathway that can leverage existing data may shorten and simplify development compared with fully novel drugs. Beyond AVERSA Fentanyl, the company is extending the same concept to other high-risk medications and also pursuing non-opioid transdermal products through its 4P Therapeutics unit, such as a patch-based approach for diabetes care. Additional contract manufacturing and R&D services add another dimension, though the main value driver remains the success of its abuse-deterrent and broader transdermal pipeline. As with all early-stage biotech R&D, the upside rests on scientific, regulatory, and commercial success that is still uncertain.

Summary

Overall, Nutriband is a very early-stage, pre-revenue biotech with a narrow but differentiated focus: making high-risk drugs safer to use through abuse-deterrent transdermal technology. Financially, it operates on a small base, with recurring losses, no meaningful revenue yet, and a reliance on equity capital and partnerships rather than debt. Strategically, it has an interesting combination of specialized technology, broad patent coverage, and a notable manufacturing partner, but its position will only be proven if it can move its lead products through the FDA process and into the market. The main opportunities lie in turning its AVERSA platform into a commercially adopted standard for certain patches, while the main risks center on regulatory outcomes, funding needs, execution complexity, and the challenge of building commercial scale as a small player in a highly regulated, competitive healthcare landscape.

NEWS

November 24, 2025 · 7:00 AM UTC

Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference

Read more

October 28, 2025 · 11:05 AM UTC

REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

Read more

October 28, 2025 · 7:00 AM UTC

Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

Read more

October 10, 2025 · 7:00 AM UTC

Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

Read more

October 8, 2025 · 8:30 AM UTC

Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology

Read more